Ann: Presentation to Investors, page-69

First time poster, long time BIT follower.

I had a read through the slides/presentation and here are my thoughts based on my medical research background.

- Slides 1-8 provide a very generic outline of the project, this is obviously important to lay people/investors, but doesn’t add anything new.

- Slide 9 is a good justification to why they are pursuing COVID-19 as a focus area, however I feel that having stats/figures would’ve made it more impactful.

- Slide 10 is great, however it is from the previous mouse-model journal article. In brief, small sample size (number of mice) limits its impact, great mouse survival numbers, looks to have a significant clearing effect, etc.

- Slide 11 is in the same format as COVID-19 on Slide 8, but has more statistics supporting it, therefore more impactful. That said, there are no references to where they got these numbers from and as such this oversight would’ve been brutalised by any researchers in the audience. Presentations MUST be referenced.

- Slide 12-13 are generic, mostly for lay people I assume.

- Slide 14/end.

Overall it doesn’t look like it adds anything new, possibly just filling the space until the ‘headline’ results are released later in the year. It also looks like it was designed for lay people in mind, except for the Slide 10 results rehash, which was relatively impactful for any audience member that has not seen the results already.

looking forward to the headline results soon.